In accordance, adjuvant epigenetic therapy with low-dose DNMT and HDAC inhibitors disrupts the premetastatic niche by blocking the trafficking of MDSCs through the downregulation of CCR2 and CXCR2 and also favouring MDSC differentiation into anti-tumour macrophage-like cells [92]. Here, CCR2 is linked to neoplasm.